Clinical · Molecular biology
A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma
Summary
An in vivo CRISPR screen identified BAP1 as a potent tumor suppressor in undifferentiated pleomorphic sarcomas (UPS). BAP1-deficient sarcomas exhibit a markedly immunosuppressive tumor microenvironment. Researchers found that PLK1 is required for the growth and survival of these sarcomas, with elevated expression in human UPS where BAP1 is reduced. Pharmacologic inhibition of PLK1 with volasertib significantly suppressed tumor growth in mouse models. Furthermore, combining PLK1 inhibition with anti-PD-1 therapy enhanced tumor control and improved survival.
Critical appraisal
Molecular biology. This study utilized a tailored in vivo CRISPR/Cas9 screen to identify BAP1 as a key tumor suppressor in soft-tissue sarcomas. Integrative analyses, including RNA sequencing, multiplex immunohistochemistry, and flow cytometry, revealed that BAP1 deficiency leads to a markedly immunosuppressive tumor microenvironment. The discovery that PLK1 is a therapeutic vulnerability in BAP1-deficient sarcomas, with elevated expression when BAP1 is reduced, represents a significant translational advance, paving the way for identifying predictive biomarkers. Clinique: The findings suggest a promising therapeutic strategy for BAP1-deficient soft-tissue sarcomas. PLK1 inhibition with volasertib, alone or in combination with anti-PD-1 therapy, demonstrated significant efficacy in syngeneic and autochthonous mouse models. This combination could potentially alter clinical practice for a subset of sarcoma patients, warranting phase I/II clinical trials to evaluate this approach. The time to clinical impact could be 3-5 years, pending human validation.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology